Project Grant R01HL177965
Award Date
1/10/25
Completion Date
11/30/28
Dollars Obligated
$618K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
This federal Project Grant award of $393,750 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project focused on developing a computational approach for predicting and preventing arrhythmias, a leading cause of sudden cardiac death. The project aims to discover effective antiarrhythmic drug therapies and optimal clinical markers for arrhythmia risk prediction by leveraging mathematical modeling,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to uncover the prevalence and biological roles of protein arginylation, a critical post-translational modification, in cardiovascular development and disease. The $633,720 award, effective January 25, 2025 through November 30, 2028, aims to: 1) establish a chemical proteomics platform to comprehensively profile arginylation sites in cardiac cell and...
This Project Grant award of $769,761 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Weill Medical College of Cornell University supports research to investigate the mechanisms by which obesity leads to atrial fibrillation. The research aims to 1) dissect the role of the nicotinamide adenine dinucleotide (NAD+) pathway in obesity-induced atrial fibrillation, and 2) assess the role of the ATF6 endoplasmic reticulum stress pathway in this...
This $653,854 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of the grant is to study the impact of cardiomyocyte-selective modulation of natriuretic peptide signaling pathways on cardiomyopathy progression and ventricular arrhythmia susceptibility in preclinical models. The specific aims are to: 1) Define how cardiomyocyte-specific modulation of PKG1 activity modifies cardiomyopathy...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $644,687 to the University of Missouri System to investigate a critical forebrain-brainstem neural circuit that contributes to the adaptive and maladaptive cardiorespiratory responses to chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnea. The research aims to resolve how this "orexin-CRH-NTS" circuit facilitates the peripheral...
This Project Grant award of $721,041 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of cardiac circadian clock misalignment in promoting ventricular arrhythmias and sudden cardiac arrest. The research will use a combination of donor human hearts and a swine model of chronic ischemia to determine if a diurnal window of arrhythmia vulnerability exists, examine the extent of cardiac circadian...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $522,794 to the University of Illinois to conduct research on the role of the voltage-gated proton channel HV1 in the pathogenesis of pulmonary hypertension. The key objectives are to use transgenic mouse models and complementary in vivo approaches to delineate how HV1 contributes to the development and progression of pulmonary hypertension. The research aims to...
The University of Connecticut Health Center received a $615,006 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program. The award, effective December 15, 2024 through November 30, 2028, will fund research to reclassify and determine the pathogenicity and pathophysiology of variants of unknown significance in the TNNT2 gene, which encodes an essential component of the cardiac sarcomere. Key research activities...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,156,992 to the University of Utah to explore the role of ceramides as a mediator of diastolic heart failure. The research aims to determine if ceramides are necessary and sufficient for driving the structural and functional changes underlying diastolic heart failure, which has few effective therapies. The project will use genetic manipulation and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding a $473,096 research project at the University of Utah to investigate the role of direct mitochondrial lactate oxidation in heart failure. The 5-year project, which began on January 1, 2025, aims to quantify direct versus indirect mitochondrial lactate oxidation in cardiac health and disease models, determine if mitochondrial-localized lactate...